Univest
Univest
  • Markets

3 Cement and Wall Putty Maker, Pharmaceutical Ingredients Company and Defence Explosives Maker Stocks With a Strong Future Roadmap: JK Cement, Granules India and Premier Explosives

  • November 17, 2026
  • Posted by: Ankit Jaiswal
  • Category: Best Stocks
No Comments
3 Cement and Wall Putty Maker, Pharmaceutical Ingredients Company and Defence Explosives Maker Stocks With a Strong Future Roadmap: JK Cement, Granules India and Premier Explosives

JK Cement, Granules India and Premier Explosives: ROE of 11.7% to 15.8% and FY22 to FY26 revenue CAGR of 9.2% to 20.8%. Prices as of 16 Nov 2026.

Quick Answer

The three cement, drug ingredient and explosives stocks to watch are JK Cement, Granules India and Premier Explosives. Their return on equity ranges from 11.7% to 15.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.2% to 20.8%. Premier Explosives leads on both return on equity at 15.8% and revenue growth at 20.8% a year. Prices are based on the 16 November 2026 close, and this article is educational, not investment advice.

Cement, drug ingredient and explosives stocks offer a focused view of a sector where demand keeps widening. JK Cement, Granules India and Premier Explosives cover a cement and wall putty maker, a pharmaceutical ingredients company and a defence explosives maker.

This list covers three cement, drug ingredient and explosives stocks with complete current figures: JK Cement, Granules India and Premier Explosives. Every figure comes from the latest reported financials and the 16 November 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

Table of Contents

Toggle
  • What Are Cement, Drug Ingredient and Explosives Stocks?
  • Cement, Drug Ingredient and Explosives Stocks at a Glance
  • Why Do Cement, Drug Ingredient and Explosives Stocks Have a Strong Roadmap in India?
  • Why JK Cement Features Among These Cement, Drug Ingredient and Explosives Stocks
  • Why Granules India Features Among These Cement, Drug Ingredient and Explosives Stocks
  • Why Premier Explosives Features Among These Cement, Drug Ingredient and Explosives Stocks
  • JK Cement vs Granules India vs Premier Explosives on Key Financials
  • Key Risks to Check Before Investing in Cement, Drug Ingredient and Explosives Stocks
  • Final Thoughts on Cement, Drug Ingredient and Explosives Stocks
    • What are cement, drug ingredient and explosives stocks?
    • Which cement, drug ingredient and explosives stocks are covered in this list?
    • Why do cement, drug ingredient and explosives stocks have a strong future roadmap in India?
    • How has JK Cement performed financially?
    • How has Granules India performed financially?
    • How has Premier Explosives performed financially?
    • What risks should investors check before buying cement, drug ingredient and explosives stocks?
    • Is this list of cement, drug ingredient and explosives stocks investment advice?

What Are Cement, Drug Ingredient and Explosives Stocks?

Cement, drug ingredient and explosives stocks are listed companies that make grey and white cement and wall putty for homes and infrastructure, make pharmaceutical ingredients and finished tablets, and make propellants and explosives for defence and space programmes. Their earnings depend on construction activity, medicine demand and defence orders.

Cement, Drug Ingredient and Explosives Stocks at a Glance

Company CMP (Rs) Market Cap (Rs Cr) P/E Industry P/E ROE (%) D/E
JK Cement 5,252.6 37,671 40.1 29.1 14.1 0.88
Granules India 798.95 22,002 33.2 36.0 11.7 0.30
Premier Explosives 554.4 3,722 111.0 48.1 15.8 0.11

On valuation, Granules India trades at a P/E below the industry P/E, while JK Cement and Premier Explosives trade above it, which reflects the growth the market already expects. Readers comparing cement, drug ingredient and explosives stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.

Why Do Cement, Drug Ingredient and Explosives Stocks Have a Strong Roadmap in India?

Cement, drug ingredient and explosives stocks have a strong roadmap in India because heavy spending on housing and roads, steady demand for essential medicines and rising defence and space spending keep widening the market for these companies.

  • Cement and putty. Roads and homes need quality finishing.
  • Pharma ingredients. Medicine makers need reliable supply.
  • Defence explosives. Defence programmes need dependable propellants.

Why JK Cement Features Among These Cement, Drug Ingredient and Explosives Stocks

Among the cement, drug ingredient and explosives stocks on this list, JK Cement is a cement and building products company with plants in northern, western and southern India. It sells grey cement, white cement and wall putty, and it has a strong presence in the premium white cement segment.

Revenue rose from Rs 8,134 crore in FY22 to Rs 13,917 crore in FY26, a compound annual growth rate of 14.4%. Net profit grew from Rs 679 crore in FY22 to Rs 988 crore in FY26, which works out to a compound annual growth rate of 9.8%.

In the June 2026 quarter, revenue grew 19.4% year on year to Rs 4,071 crore. The company has a return on equity of 14.1%, a debt to equity ratio of 0.88 and a market capitalisation of Rs 37,671 crore. The stock trades at a P/E of 40.1, above the industry P/E of 29.1.

Roadmap: The company is expanding grey cement capacity in several regions and growing its white cement and putty range, which carries a strong brand. Housing and infrastructure activity supports steady cement demand.

What to watch: Track capacity additions, volume growth and realisation per tonne.

Why Granules India Features Among These Cement, Drug Ingredient and Explosives Stocks

Among the building cement, tablet maker and defence propellant shares on this list, Granules India is a Hyderabad-based pharmaceutical manufacturer that makes active ingredients, intermediates and finished dosage forms, with a strong position in paracetamol, metformin and ibuprofen.

In the June 2026 quarter, revenue grew 20.6% year on year to Rs 1,479 crore, while net profit rose 59.8% to Rs 180 crore. Revenue rose from Rs 3,783 crore in FY22 to Rs 5,386 crore in FY26, a compound annual growth rate of 9.2%.

Net profit grew from Rs 413 crore in FY22 to Rs 595 crore in FY26, which works out to a compound annual growth rate of 9.6%. The company has a return on equity of 11.7%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 22,002 crore. The stock trades at a P/E of 33.2, below the industry P/E of 36.0.

Roadmap: The company is shifting its mix towards finished dosages, which earn better margins than ingredients, and it supplies customers in regulated markets, especially the United States. Capacity additions and new product approvals support steady growth.

What to watch: Monitor new product approvals and the share of finished dosages in total sales.

Why Premier Explosives Features Among These Cement, Drug Ingredient and Explosives Stocks

Among the three companies on this list, Premier Explosives makes industrial explosives, detonators, propellants and defence products, and is a supplier of rocket motors and solid propellants for strategic and space programmes.

The company has a return on equity of 15.8%, a debt to equity ratio of 0.11 and a market capitalisation of Rs 3,722 crore. The stock trades at a P/E of 111.0, above the industry P/E of 48.1.

Revenue rose from Rs 202 crore in FY22 to Rs 430 crore in FY26, a compound annual growth rate of 20.8%. Net profit grew from Rs 5.2 crore in FY22 to Rs 45.8 crore in FY26, which works out to a compound annual growth rate of 72.1%.

Roadmap: The company is moving up the value chain into defence and space propellants, which carry higher margins than civil explosives. Orders from strategic programmes and capacity expansion support the plan.

What to watch: Check the execution of defence and space orders, which can be uneven from one quarter to the next.

JK Cement vs Granules India vs Premier Explosives on Key Financials

The table below sets the three cement, drug ingredient and explosives stocks side by side on revenue, profit and margin, using reported figures.

Company FY22 Revenue (Rs Cr) FY26 Revenue (Rs Cr) Revenue CAGR (FY22-FY26) FY26 Net Profit (Rs Cr) FY26 Net Margin
JK Cement 8,134 13,917 14.4% 988 7.1%
Granules India 3,783 5,386 9.2% 595 11.0%
Premier Explosives 202 430 20.8% 45.8 10.6%

Premier Explosives posts the highest return on equity in this group at 15.8%. JK Cement has the largest FY26 revenue at Rs 13,917 crore, and Premier Explosives shows the fastest revenue growth with a 20.8% compound annual rate. A useful habit with cement, drug ingredient and explosives stocks is to check each new quarterly result against the capacity plans the company described earlier.

Key Risks to Check Before Investing in Cement, Drug Ingredient and Explosives Stocks

Every theme carries risks that deserve a check before any decision. For these cement, drug ingredient and explosives stocks, the main points are: Long-term building cement, tablet maker and defence propellant shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

  • Raw material costs. Ingredient and packaging prices can move margins.
  • Regulatory approvals. Plant inspections and approvals can affect supplies.
  • Order timing. Defence and space orders can shift between periods.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter cement, drug ingredient and explosives stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Cement, Drug Ingredient and Explosives Stocks

Cement, drug ingredient and explosives stocks reward patient research into demand, execution and financial strength. JK Cement, Granules India and Premier Explosives each have a clear plan to grow. Based on the 16 November 2026 close, JK Cement trades at Rs 5,252.6, Granules India at Rs 798.95 and Premier Explosives at Rs 554.4.

Download the Univest iOS App or Univest Android App to track cement, drug ingredient and explosives stocks, set price alerts and get research-backed stock ideas.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

What are cement, drug ingredient and explosives stocks?

Ans. Cement, drug ingredient and explosives stocks are listed companies that make grey and white cement and wall putty for homes and infrastructure, make pharmaceutical ingredients and finished tablets, and make propellants and explosives for defence and space programmes. Their earnings depend on construction activity, medicine demand and defence orders. This list looks at three of them, JK Cement, Granules India and Premier Explosives, using reported FY22 to FY26 financials and the 16 November 2026 closing prices.

Which cement, drug ingredient and explosives stocks are covered in this list?

Ans. This list covers JK Cement, Granules India and Premier Explosives. Based on the 16 November 2026 close, JK Cement traded at Rs 5,252.6, Granules India at Rs 798.95 and Premier Explosives at Rs 554.4. Their return on equity ranges from 11.7% to 15.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.2% to 20.8%.

Why do cement, drug ingredient and explosives stocks have a strong future roadmap in India?

Ans. Cement, drug ingredient and explosives stocks have a strong roadmap in India because heavy spending on housing and roads, steady demand for essential medicines and rising defence and space spending keep widening the market for these companies. The main drivers are as follows. Cement and putty. Roads and homes need quality finishing. Pharma ingredients. Medicine makers need reliable supply. Defence explosives. Defence programmes need dependable propellants. Together these factors give the companies on this list a visible path for growth over the coming years.

How has JK Cement performed financially?

Ans. Revenue rose from Rs 8,134 crore in FY22 to Rs 13,917 crore in FY26, a compound annual growth rate of 14.4%. Net profit grew from Rs 679 crore in FY22 to Rs 988 crore in FY26, which works out to a compound annual growth rate of 9.8%. In the June 2026 quarter, revenue grew 19.4% year on year to Rs 4,071 crore. The company has a return on equity of 14.1%, a debt to equity ratio of 0.88 and a market capitalisation of Rs 37,671 crore. The stock trades at a P/E of 40.1, above the industry P/E of 29.1. Looking ahead, the company is expanding grey cement capacity in several regions and growing its white cement and putty range, which carries a strong brand. Housing and infrastructure activity supports steady cement demand.

How has Granules India performed financially?

Ans. Revenue rose from Rs 3,783 crore in FY22 to Rs 5,386 crore in FY26, a compound annual growth rate of 9.2%. Net profit grew from Rs 413 crore in FY22 to Rs 595 crore in FY26, which works out to a compound annual growth rate of 9.6%. In the June 2026 quarter, revenue grew 20.6% year on year to Rs 1,479 crore, while net profit rose 59.8% to Rs 180 crore. The company has a return on equity of 11.7%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 22,002 crore. The stock trades at a P/E of 33.2, below the industry P/E of 36.0. Looking ahead, the company is shifting its mix towards finished dosages, which earn better margins than ingredients, and it supplies customers in regulated markets, especially the United States. Capacity additions and new product approvals support steady growth.

How has Premier Explosives performed financially?

Ans. Revenue rose from Rs 202 crore in FY22 to Rs 430 crore in FY26, a compound annual growth rate of 20.8%. Net profit grew from Rs 5.2 crore in FY22 to Rs 45.8 crore in FY26, which works out to a compound annual growth rate of 72.1%. The company has a return on equity of 15.8%, a debt to equity ratio of 0.11 and a market capitalisation of Rs 3,722 crore. The stock trades at a P/E of 111.0, above the industry P/E of 48.1. Looking ahead, the company is moving up the value chain into defence and space propellants, which carry higher margins than civil explosives. Orders from strategic programmes and capacity expansion support the plan.

What risks should investors check before buying cement, drug ingredient and explosives stocks?

Ans. Investors should check a few risks before buying cement, drug ingredient and explosives stocks. Raw material costs. Ingredient and packaging prices can move margins. Regulatory approvals. Plant inspections and approvals can affect supplies. Order timing. Defence and space orders can shift between periods. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of cement, drug ingredient and explosives stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 16 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.



Best Stocks building cement Cement construction material drug ingredient and explosives stocks Granules India JK Cement pharma ingredients and defence supplies stocks Premier Explosives tablet maker and defence propellant shares
Author: Ankit Jaiswal
Ankit Jaiswal is the Senior Research Analyst at Univest, leading the platform's in-house equity research desk and serving as the editorial reviewer for all research and blog content published at univest.in. With 11+ years of experience in Indian equity markets, he oversees stock recommendations, earnings analysis, sector coverage, and ensures every published article meets SEBI Research Analyst Regulations. He holds a Bachelor of Commerce (B.Com) from St. Xavier's College, Kolkata — one of India's most prestigious commerce institutions — and has cleared CMT Level 2 from the CMT Association, a globally recognised certification in technical analysis and market research. His research methodology combines fundamental analysis (earnings quality, balance sheet strength, management commentary) with advanced technical analysis (chart patterns, momentum indicators, market structure) — giving Univest's retail investors a dual-lens approach that most Indian research platforms lack. Ankit is among the most comprehensively certified analysts in Indian financial media, holding five NISM certifications: Series-XV (Research Analyst), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-VI (Depository Operations), and Series-V-A (Mutual Fund Distributors). At Univest — India's SEBI-registered research and advisory platform — Ankit's responsibilities include leading the research team, finalising stock recommendations published across Pro Lite, Pro Super, and Pro Gold advisory services, and maintaining editorial oversight of all YMYL financial content published on the blog.

Leave a Reply Cancel reply